Exclusive: Canadian regulator considers changes to new drug pricing plan

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Exclusive: Canadian regulator considers changes to new drug pricing plan

Rogers (ROG) Tops Q4 EPS by 8c, Revenues Miss; Offers Q1 EPS/Revenue Guidance Below Consensus

February 20, 2020 4:17 PM EST

Rogers (NYSE: ROG) reported Q4 EPS of $1.14, $0.08 better than the analyst estimate of $1.06. Revenue for the quarter came in at $193.8 million versus the consensus estimate of $204.87 million.

For 2019 Rogers reported modest growth in revenue and adjusted earnings, despite challenging market conditions in the second half of the year, stated Bruce D. Hoechner, Rogers' President and CEO. "Fourth quarter revenues were impacted by expected weakness... More